key: cord-0690285-nds2dcrk authors: Westhoff, Whitney J.; Smith, Louisa H.; Wyszynski, Diego F.; Hernandez‐Diaz, Sonia title: COVID‐19 pharmacotherapy utilization patterns during pregnancy: International Registry of Coronavirus Exposure in Pregnancy date: 2022-04-24 journal: Pharmacoepidemiol Drug Saf DOI: 10.1002/pds.5440 sha: ef782de45bb63a16cbe39c92db2cc11256233c44 doc_id: 690285 cord_uid: nds2dcrk PURPOSE: Women infected with SARS‐CoV‐2 during pregnancy are at increased risk of developing severe illness and experience a higher rate of preterm births than pregnant women who are not infected. The use of innovative or repurposed therapies to treat COVID‐19 patients is widespread; however, there are very limited data regarding the patterns of use and safety profile of most of these therapeutics in pregnant women. We assessed the patterns of use of COVID‐19 therapeutics during pregnancy using data from the International Registry of Coronavirus in Pregnancy (IRCEP). METHODS: The IRCEP is an international observational cohort study intended to assess the risk of major obstetric and neonatal outcomes among pregnant women with COVID‐19. Women enrolled while pregnant or within 6 months after end of pregnancy. Follow‐up for women enrolled while pregnant includes monthly online questionnaires throughout the pregnancy and, for live births, through the infant's first 90 days of life. Participants provide information on demographic characteristics, health history, COVID‐19 tests and symptoms, medications, and obstetric and neonatal outcomes. RESULTS: A total of 5780 women with COVID‐19 during pregnancy were identified from the IRCEP. Severity of COVID‐19 was classified in 372 of them as severe, 3053 moderate, and 2355 mild. The most frequently reported COVID‐19 therapies, other than analgesics, included azithromycin (12.8%), steroids (3.5%), interferon (2.4%), oseltamivir (2.1%), chloroquine/hydroxychloroquine (1.7%), anticoagulants (2.0%), antibodies (0.9%), and remdesivir (0.3%). Most drugs were preferentially used for severe cases. Patterns of use varied by country. CONCLUSIONS: IRCEP participants reported use of therapeutics for COVID‐19 during pregnancy for which there is little safety information. Findings on COVID‐19 pharmacotherapy utilization patterns can guide future studies examining the safety of COVID‐19 therapies during pregnancy. • A total of 5780 participants from an international, observational cohort of women were identified with COVID-19 during pregnancy and reported pharmacotherapy use. • The most frequently reported COVID-19 therapies, other than analgesics, included azithromycin, steroids, interferon, oseltamivir, chloroquine/hydroxychloroquine, and antibodies. • COVID-19-specific medications were reported to be used more frequently among patients with severe disease than in those with lower severity. Therapy use patterns varied by country but not notably between trimesters of infection. • IRCEP participants reported use of therapeutics for COVID-19 during pregnancy for which there is little safety information. Pregnant women infected with SARS-CoV-2 may develop severe COVID-19 and require treatment. Despite this, little is known about the patterns of use and safety of many COVID-19 medications in pregnancy. In an international study of 5780 women with COVID-19 during pregnancy, we evaluated the utilization of medications for COVID-19 in pregnancy. Therapy use patterns varied by disease severity and country, but not notably between trimesters of infection. Participants reported use of medications for COVID-19 during pregnancy for which there is little safety information. Women infected with SARS-CoV-2 during pregnancy are at risk of developing severe illness and experience a higher rate of preterm births than pregnant women who are not infected. 1-4 Therefore, pregnant patients with symptomatic SARS-CoV-2 infection have been, and will be, treated to prevent or cure severe COVID-19. 5 A number of therapeutics have been approved or authorized for treatment of COVID-19 in various countries, such as remdesivir, favipiravir, baricitinib, tocilizumab, and more recently casirivimab/ imdevimab and sotrovimab, among others. Investigational use of repurposed medications to treat COVID-19 also remains high, with some research showing safety in pregnancy for repurposed medications based on experience with other indications. [6] [7] [8] [9] However, there remains an overall dearth of knowledge about the usage patterns and safety profile of many of these therapeutics in pregnant women and their developing offspring. 10 Venues for increasing awareness included social media channels frequently visited by pregnant women (e.g., Facebook) and online parenting forums. Women enrolled while pregnant completed short monthly online questionnaires throughout pregnancy and for 90 days after delivery for live births. Women enrolled after pregnancy completed a retrospective questionnaire covering the same information as those enrolled during pregnancy. Participants provided detailed information on COVID-19 tests, specific symptoms, date, and gestational timing of test and symptoms, and indicators of disease severity. Additional information collected includes demographics (age, race/ethnicity, country of residence, and education), pre-pregnancy body mass index, gestational age, health history, use of medications, and obstetric and neonatal outcomes. More detailed information about the IRCEP can be found elsewhere. 12 We included all women with symptomatic COVID-19 during pregnancy based on a positive laboratory test or clinical diagnosis. They were subsequently categorized into one of three levels of COVID-19 severity using the following criteria: (1) severe COVID-19: self-report of being admitted to the ICU, needing respirator assistance, ECMO, or ventilation, or who were hospitalized with organ failure, pneumonia, acute respiratory distress syndrome, abnormal chest X-ray or CT scan, chest pain, blue lips, or breathing difficulties; (2) moderate COVID-19: those with pneumonia, respiratory distress, or breathing difficulties without hospitalization, or who were hospitalized or reported to the ER or clinic with upper respiratory symptoms, fatigue or myalgia, a fever above 38 C, loss of taste or smell, headache, diarrhea, nausea, or vomiting; and (3) mild COVID-19: any other symptoms of lesser severity than those of moderate or severe COVID-19. All pharmacotherapy information was collected via online selfreported surveys. Participants responded "Yes" or "No" to the question: Did you take any medication during pregnancy to treat COVID-19? If they chose "Yes," they were prompted to select from a menu of COVID-19 approved and authorized treatments, including repurposed medications. If they chose the option "Other," they were asked to indicate the name of the medication in a free text box. We reviewed the text fields for these "Other" medications and further classified them into therapeutic groups. Other medications reported as SARS-CoV-2 treatments by a small number of participants included antidepressants, antiepileptic drugs, milk of magnesia, antacids, insulin, metformin, antihypertensives, opioids, and proton-pump inhibitors. We describe here the pharmacologic treatments used to treat COVID-19 during pregnancy in the IRCEP. We assessed (1) Use of therapies increased with disease severity for most medications ( The distribution of disease severity varied by trimester of infection; the frequency of participants with severe disease was higher in the third trimester (9.8%) than in the second (5.6%) and first (2.5%) tri- Differences in drug utilization by country were observed as well. Notably, Russia accounted for the 97.8% of self-reported use of interferon medications (135 out of a total 138 interferon users). Additionally, 52.6% of women who used remdesivir were from the In an international cohort of 5780 pregnant women with symptomatic COVID-19 during pregnancy, the most commonly reported COVID-19 treatments other than analgesics were azithromycin, cough suppressants, steroids, interferon, oseltamivir, chloroquine/hydroxychloroquine, antihistamines, and antibodies. Our findings reveal similar patterns of use found in other, nonpregnant populations with COVID-19, which showed that COVID-19-specific medications were received more frequently among patients with severe disease than in those with lower severity. 13, 14 Given the general trend of increased medication use with increased disease severity, future research on the effectiveness and safety of COVID-19 therapeutics in pregnancy will need to carefully adjust for confounding by indication. There are also limitations to the disease severity categorization, which does not have the granularity of more complex severity index methods. Participants reported use of treatments for COVID-19 during pregnancy for which there is limited safety information (Table S1 ). Evaluating the safety of these therapeutics in pregnancy should be a public health priority, since the course of disease in pregnant women with COVID-19 can be severe and treatments may be necessary. Given the lack of pregnant women included in clinical trials, observational studies play an important role in gathering pharmacoepidemiologic evidence to enable informed decision-making in the treatment of pregnant women with COVID-19. Observational studies will need to consider regional differences, trimester of exposure and disease severity. Whitney J. Westhoff and Louisa H. Smith have no conflict to declare. Sonia Hernandez-Diaz reports being an investigator on grants to her institution from Takeda for unrelated studies; and personal fees from UCB and Roche outside the submitted work. She did not receive any funding for this work. The Institutional Review Board of the Harvard T.H. Chan School of Public Health approved this study (IRB20-0622). Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis Risk factors for illness severity among pregnant women with confirmed severe acute respiratory syndrome coronavirus 2 infection-surveillance for emerging threats to mothers and babies network, 22 state, local, and territorial health departments Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status -United States Birth and infant outcomes following laboratory-confirmed SARS-CoV-2 infection in pregnancy -SET-NET, 16 jurisdictions A comprehensive review of the Management of Pregnant Women with COVID-19: useful information for obstetricians Review of investigational drugs for coronavirus disease 2019 Hydroxychloroquine early in pregnancy and risk of birth defects Safety of Tenofovir Disoproxil fumarate (TDF) for pregnant women facing the COVID-19 pandemic Pregnancy and COVID-19: pharmacologic considerations Tocilizumab for coronavirus disease 2019 in pregnancy and lactation: a narrative review A review of remdesivir for COVID-19 in pregnancy and lactation International registry of coronavirus exposure in pregnancy (IRCEP) -cohort description and methodological considerations Pharmacotherapy for hospitalized patients with COVID-19: treatment patterns by disease severity A COVID-19-ready public health surveillance system: the Food and Drug Administration's sentinel system Hospitals Are Rationing Remdesivir -WSJ COVID-19 pharmacotherapy utilization patterns during pregnancy: International Registry of Coronavirus Exposure in Pregnancy ORCID Whitney J. Westhoff https://orcid.org/0000-0003-0375-4054Sonia Hernandez-Diaz https://orcid.org/0000-0003-1458-7642